SCHEMBL792846

SCHEMBL792846

Cc1ccc2c(C3CCCCC3)c3n(c2c1)CCN(CCC1CCN(C2CCCC2)CC1)c1ccccc1-3

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 1/20 0.33
MMP12 P39900 1/20 0.33
OPRL1 P41146 4/20 0.32
OPRM1 P35372 4/20 0.32
OPRK1 P41145 4/20 0.32
OPRD1 P41143 1/20 0.32
OGFRL1 Q5TC84 1/20 0.32
SLC18A3 Q16572 1/20 0.32
ALDH1A1 P00352 2/20 0.32
ABCB1 P08183 2/20 0.31
TMEM97 Q5BJF2 1/20 0.31
SIGMAR1 Q99720 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
ALOX12 P18054 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL792836 0.89 PRKCA (0.33) PRKCAMMP12ALDH1A1KDM4EMEN1
SCHEMBL804185 0.86 PRKCA (0.45) PRKCAMMP12OPRM1OPRK1OPRD1
SCHEMBL804601 0.86 ABCB1 (0.31) PRKCAMMP12OPRL1OPRM1OPRK1
SCHEMBL10283220 0.85 OPRM1 (0.40) PRKCAMMP12OPRL1OPRM1OPRK1
SCHEMBL14572886 0.85 PRKCA (0.34) PRKCAMMP12KDM4EHPGDSMN1; SMN2
SCHEMBL792850 0.85 OPRM1 (0.31) PRKCAMMP12OPRM1OPRK1OPRD1
SCHEMBL792654 0.84 GPR119 (0.40) KDM4E
SCHEMBL792562 0.80 PRKCA (0.33) PRKCAMMP12ALDH1A1KDM4EMEN1
SCHEMBL792424 0.79 PRKCA (0.41) PRKCAMMP12ALDH1A1KDM4EMEN1
SCHEMBL12427649 0.78 PRKCA (0.45) PRKCAMMP12ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 PRKCA 2404/4885MMP12 1013/4885OPRL1 4372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.